Mayne Pharma Group (ASX:MYX) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


ASX:MYX Mayne Pharma Group Ltd ASX:MYX
51 GF Score
Price A$2.57
GF Value A$5.31
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mayne Pharma Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASX:MYX vs MCK, COR, CAH: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group Margin of Safety % (DCF Earnings Based) vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Margin of Safety % (DCF Earnings Based) falls into.


ASX:MYX
51GF Score
Mayne Pharma Group Ltd ASX:MYX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for ASX:MYX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MAYNF:USA
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score

Get the complete analysis for ASX:MYX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.57
Price
A$5.31
GF Value